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Abstract:  Substance P (SP) has been associated with pain, depression as well as neurodegenerative 
diseases. Many of these diverse actions of SP can potentially be attributed to SP metabolites generated 
at the blood-brain barrier (BBB). In these studies, the metabolism of SP was investigated using an in vitro 
model of the BBB and LC-MS/MS. Substance P metabolism was found to be non-saturable in the 
concentration range of 100 nM to 10 µM, with approximately 70% of the peptide remaining intact after 
5 hrs. The major metabolites of SP were identified by MS to be 3-11 and 5-11. Two previously 
unreported metabolites, 5-11 and 6-11 were also found in our studies. Several additional minor SP 
metabolites including 1-9 and 2-11 were also identified. A profile of the SP metabolites generated by the 
BBB overtime was obtained. The results from the present study provide us a better understanding of the 
role of blood-brain barrier in the pharmacology of SP. 
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Introduction: The blood-brain barrier (BBB) protects the brain and maintains homeostasis by limiting the 
entry of many blood-borne molecules and peptides. The tight junctions between the endothelial cells 
that comprise the BBB bestow the barrier properties to BBB. Understanding the interactions between 
blood-borne neuropeptides such as Substance P (SP) and BBB is of utmost interest in the design of drugs 
for pain, and neurodegenerative diseases [1-5]. Also many neuropeptides such as SP can function as 
vectors for the delivery of potent drug substances to their target sites in the brain [6]. In addition, the 
BBB is also known to express metabolic enzymes on its surface that exhibit peptidase activity, 
generating metabolites which exert their own pharmacological effects. Thus investigation of the 
metabolism of neuropeptides such as SP at the BBB interface can assist in understanding the complex 
physiological effects of major neuropeptides and their metabolites.  
 In vitro cell culture models of BBB provide the advantage of studying the metabolism and 
permeation mechanisms of drug substances without the complexity associated with in-vivo procedures. 
Further, the samples generated from these in vitro experiments require little or no sample clean up in 
comparison to the in vivo studies. The bovine-brain microvessel endothelial cell (BBMEC) system is a 
well-characterized in vitro model of the BBB and retains many properties such as efflux, transport and 
metabolic pathways of intact BBB [7]. This in vitro model has been widely used in the investigation of 
peptide metabolism, transport and binding at the BBB. Various enzymes have also been identified in the 
BBMEC model, including the angiotensin-converting enzyme (ACE), hydolyases, and peptidases [8,9]. 
 Substance P offers many sites in its structure for metabolic cleavage. The various enzymes that 
have been identified to cleave SP include ACE, aminopeptidase, neutral endopeptidase, dipeptidyl 
aminopeptidase, post-proline cleaving enzyme and SP degrading and hydrolyzing enzymes. ACE has 
been shown to be expressed in both the cytosol and the membrane surface of BBMEC. The various SP 
metabolites that are generated at the BBB are known to exert important physiological effects, including 
alteration of the levels of other neurotransmitters in the brain [10].  
An earlier report of the metabolism of SP at the BBB utilized capillary electrophoresis with laser 
induced fluorescence detection (CE-LIF) [11]. This method involved derivitization of the ε amino or lysine 
group with naphthalene dialdehyde and cyanide and thus it is limited to detecting only lysine containing 
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metabolites. Although metabolism studies with SP have been performed in vivo using LC-MS/MS [12], its 
metabolism in the BBMEC model has not been investigated. Thus the objective of the present study was 
to investigate the metabolism of SP at the BBB and identify its major metabolites using LC-MS/MS. LC-
MS/MS is capable of detecting all the metabolites of SP and is not limited to a specific functional group. 
The results from this study are compared with the in vivo studies using microdialysis sampling and with 
previous SP metabolism studies using CE-LIF.  
 
Materials and Methods 
Materials:  
Substance P 1-11, 1-4, 1-7, 1-9, 2-11 and (Tyr8) 1-11 were obtained from Bachem Biosciences 
(King of Prussia, PA, USA).  SP 3-11, 5-11 and 6-11 were acquired from Advanced ChemTech (Louisville, 
KY, USA).  Leucine-enkephalin (Leu-Enk), CaCl2, MgSO4, NaCl, KCl, Na2HPO4, KH2PO4, glucose, ascorbic 
acid, sodium bicarbonate, endothelial cell growth factor, streptomycin, horse serum, polymycin B, 
amphotericin B, heparin and penicillin G were obtained from Sigma (St. Louis, MO, USA).  Minimum 
essential media (MEM), N-2-hydroxyethylpiperazine-N’-2-ethane sulfonic acid (HEPES) and Ham F-12 
nutrient mixture (Ham’s F12) were acquired from Gibco (Long Island, NY).  Acetonitrile (ACN, HPLC 
grade) was purchased from Fisher Scientific (Fair Lawn, NJ, USA) and formic acid (99%) was from Acros 
Organics (Morris Plains, NJ, USA). 
Stock Solutions: 
A stock solution of 0.1 % formic acid (FA) in water was prepared diluting 1 mL of FA with 999 mL 
of NANOpure water (Labconco, Kansas City, MO, USA).  The solution was then filtered through a 0.22 
µm Magna nylon supported membrane filter from Osmonics (Minnetonka, MN, USA).  The same 
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procedure was used to prepare a 0.1 % FA stock solution in ACN except that instead of diluting with 
water the FA was diluted with ACN prior to filtration.  Stock solutions used for standards of SP, its 
metabolites and internal standard (IS) (Tyr8) 1-11 were made up in 0.1 % FA in water at concentrations 
of 100 µM for all compounds except SP 1-4, which was at 500 µM.  The peptide stock solutions were 
stored at 4° C in 1.5 mL polypropylene microcentrifuge tubes from Fisher Scientific (Pittsburgh, PA, USA).  
The complete culture plating media consisted of 10 mM HEPES, 13 mM sodium bicarbonate, 100 µg/ml 
of streptomycin and 100 µg/ml of penicillin G in a mixture of 50 % MEM and 50 % Ham’s F12.  The 
culture media was adjusted to pH 7.26 and sterile filtered.  For the plating media 55 ml of horse serum, 
1.25 ml of polymyxin B (20 mg/ml) and 0.125 ml of amphotericin B were added to 500 mL of the 
complete culture media.  The changing medium was also prepared similarly except that 1.1 ml of 
heparin 50mg/ml and 2.5 ml of endothelial cell growth factor were added instead of polymyxin B and 
amphotericin B solutions.  The plating media and changing media were then stored at 4° C until use.  The 
buffer used for metabolism experiments consisted of 10 mM HEPES in 50 % MEM and 50 % Ham’s F12. 
LC-MS/MS parameters 
All separations were performed using a Waters 2690 HPLC system (Waters, Milford, MA, USA), 
which contained a refrigerated autosampler (maintained at 4° C) and a column heater unit (maintained 
at 25° C).  Samples were placed in 250 µL volume polypropylene autosampler vials (Fisher Scientific, 
Pittsburgh, PA, USA) and 25 µL was injected for each sample.  The samples were analyzed using a 1.0 x 
50 mm Vydac C-18 analytical column with 5 µm particles (Grace Vydac, Hesperia, CA, USA).  The HPLC 
separation of SP and its metabolites was accomplished using a flow rate of 0.2 µL/min and gradient 
elution.  For the gradient parameters, Solvent A was 0.1 % FA in water and Solvent B was 0.1 % FA in 
ACN.  The gradient used for the separation was: 100 % A (0.1 % FA in water) from 0 to 2 minutes, a 
linear ramp from 2 to 5 minutes going from 100 % A to 75 % A and 25 % B (0.1 % FA in ACN), holding at 
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75 % A and 25 % B from 5 to 6 minutes, a linear return from 5 to 10 minutes going from 75 % A and 25 % 
B to 100 % A, and a 5 minute equilibration from 10 to 15 minutes at 100 % A before the next injection.  
The column was connected to the HPLC system by 60 cm of 0.05” PEEK tubing (Upchurch Scientific, Oak 
Harbor, WA, USA) and was connected to the detector by 50 cm of 0.07” PEEK tubing (Upchurch 
Scientific). Tandem MS detection was accomplished using a Micromass Quattro Micro (Waters, Milford, 
MA, USA) in electrospray positive ionization mode (ESI+).  The MS/MS settings are listed in Tables 1 and 
2.  
 
 Investigation of SP metabolism in vitro using BBMECs 
 The BBMECs were isolated from the gray matter of bovine brains (see ref 13 for details). The 
BBMECs were then plated on a 12-well tissue culture plate using plating media. After 3 days, the media 
was replaced every alternate day until the cells were grown to reach a confluent monolayer. 
Metabolism studies were conducted with the BBMECs after they had attained confluency. The 
metabolism of SP was investigated in the BBMECs using solutions of SP (100 nM, 1 µM or 10 µM SP) 
made up in 10 mM HEPES in 50 % MEM and 50 % Ham’s F12 for metabolism studies.  Before the 
metabolism studies were initiated, the growth media in the plate was removed and the cells were rinsed 
with the above solution. The temperature was maintained at 37° C by placing the 12-well plate in a 
heated water bath.  Following this, 2 mL of a SP solution was added to 9 of the 12 wells.  The rest of the 
wells contained blank solution as a control. Substance P stability in the solution was also simultaneously 
investigated in a separate 24-well plate. Sixty microliter (60 µL) aliquots were taken out over a period of 
5 hours from the wells at different time intervals and diluted with 48 µL of 0.1% FA and 12 µL of 10 µM 
IS in 0.1% FA.  These samples were then stored at -20° C until analyzed by LC-MS/MS for metabolism 
products. 
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Results and Discussion 
Analytical method 
An electrospray LC-MS/MS method for the detection of SP and its metabolites in cell culture 
samples was developed. The advantages of LC-MS/MS technique over previous analytical methods for 
SP and its metabolites include, (i) the ability to detect compounds based on mass-to-charge (m/z) ratio, 
(ii) no need for sample derivatization (fluorescence and immuno assay based methods), (iii) does not 
generate radioactive waste, (iv) short chromatographic runs, (v) amenable to automation, and (vi) 
excellet sensitivity and selectivity. Although other mass spectrometric techniques (such as MALDI) can 
be used for peptide identification, LC-MS/MS remains the choice for quantitative analysis of peptides 
[14]. Electrospray ionization in the positive mode was selected as the method for the detection of SP 
and its metabolites. The hydrophilic nature of the peptide and the presence of ionic residues in SP 
structure make the compound readily ionizable under ESI+ conditions, thus improving the sensitivity of 
the assay. The mobile phase for the analysis is composed of an acidic aqueous phase (0.1% formic acid) 
with an organic modifier (acetonitrile).  
 Using this LC-MS/MS method, with (Tyr8)-SP as internal standard, chromatographic separation 
of SP and its the fragments resulted in well resolved peaks without any issues of co-elution and cross-
talk among the compounds (Fig. 1). The linearity and linear range was assessed for SP and each of the 
metabolites (see Table 3 for results).  The linearity (r2) was greater than 0.97 for all 8 compounds and 
with the exception of SP 1-4; the linear range was from 1 or 2 nM to at least 500 nM.  The LC-MS/MS 
was also a very sensitive assay with a LOD of 2 nM or less for all compounds except SP 1-4 (Table 3).  The 
lack of linear range and sensitivity for SP 1-4 is likely due to ion suppression by co-eluting salts from the 
cell media.  The final method required minimal sample preparation (only dilution and addition of 
internal standard), and no derivatization. The MS based method could also be automated and had a 
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separation time of less than 10 minutes and a 15-minute total analysis time (5 min for column 
equilibration between runs).  
 
SP metabolism with BBMECs 
Prior to the investigation of metabolism of SP by BBMEC, the use of buffer solution as a 
satisfactory medium for conducting the metabolism studies was confirmed. The stability of SP in the 
buffer solution without the presence of cells was determined by storing it in a polypropylene tube at 4º 
C for 48hrs (Fig. 2a) and at 37º C for 24hrs (Fig. 2b). The solutions showed no signs of degradation.  
Figure 2c shows a TIC chromatogram obtained after 5 hours from a well containing cells, but no SP.  The 
only peak observed is that of the internal standard which was added to the sample prior to injection.  
Figure 2d shows a TIC chromatogram at the 5 hour time point of a well at 37º C with no cells, but 
containing 10 µM SP.  In this figure, a trace amount of degradation of SP was detected (3-11); however, 
this degradation was less than 0.1 % of the SP peak and therefore was not likely to cause a problem with 
metabolite quantitation.  No peaks were observed in the wells containing the buffer solution without 
any cells. Chromatograms obtained from the incubation of 10 µM SP with BBMECs for 5 hrs are shown in 
Fig. 3 (low intensity metabolites) and Fig. 4 (high intensity metabolites). The concentration-time profile 
for formation of SP metabolites over the 5-hour period is shown in Fig. 5. Substance P 3-11 and 1-7 were 
the major metabolites detected. Smaller amounts of SP 1-4, 1-7, 1-9, 2-11 and 5-11 were also found. 
After 5 hours, 70 % of SP was found to remain intact and unmetabolized in the buffer.  
The metabolism of SP was also investigated at lower concentrations (1 µM and 100 nM) to 
determine if the metabolite profile changes with concentration. These concentrations were closer to 
those observed physiologically (Fig. 6 and 7). The major metabolite generated at high concentrations (1 
µM and 100 nM) was SP 3-11; however, at 100 nM SP, the concentration of SP 3-11 generated was 
Chappa, A.K., Cooper, J.D., Audus, K.L., and Lunte, S.M. (2007) Investigation of the metabolism of Substance-P at the blood-
brain barrier using LC-MS/MS.  J. Pharm. Biomed. Anal.43, 1409-1415.  PMID: 17118606.  Publisher’s official version: 
<http://dx.doi.org/10.1016/j.jpba.2006.10.005> .  Open Access version:  http://kuscholarworks.ku.edu/dspace/. 
8 
 
similar in magnitude to that of SP 5-11 and SP 6-11. Only 3 metabolites could be detected from the 
incubation at 100 nM, due to the sensitivity limit of the LC-MS/MS method. However at 1 µM SP, all the 
metabolites except 1-4 could be detected and quantified.  
 
Metabolism comparison with the in vivo study and previous in vitro studies 
 The in vitro results described here indicate that SP 3-11 is the major metabolite formed at the 
BBB and that SP 2-11, while detected, occurs at a much lower concentration than any of the other 
metabolites monitored. These results were compared to previous in vivo metabolism studies [15-18]. In 
vivo brain microdialysis studies conducted in our lab using LC-MS/MS have shown that SP 1-7 and SP 3-
11 were the major metabolites in the striatum. In addition, SP 2-11 was observed as a minor metabolite 
in these studies [17]. These results correlate very well with those observed in vitro using the BBMECs; SP 
3-11 and SP 1-7, at 10 µM SP, were the major metabolites and SP 2-11 was the metabolite that occurred 
at the lowest concentration. 
             Previous work in our lab on SP metabolism using BBMECs and CE-LIF detection also found SP 3-11 
as the major metabolite [11]. Other groups have reported SP 5-11 and SP 6-11 [12] and SP 1-7 and SP 1-
4 [16] as the major metabolites of SP in vivo. Our laboratory is the only group to report the appearance 
of SP 2-11 as a metabolite both in vivo with rats or in vitro with the BBMEC cell culture model.  Because 
SP 2-11 occurs at very  low concentrations (nM), a very sensitive analytical method was necessary for its 
detection.   
 
 Enzymatic cleavages and physiological importance of metabolites 
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 Many of the metabolites of SP (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) have been 
shown to exhibit important physiological effects. The major metabolite detected in the LC-MS/MS 
experiments, (SP 3-11) results from the cleavage of SP by endopeptidase EC 3.4.21.26, a post-proline 
cleaving enzyme [20, 21].  This metabolite has been shown to cause a SP-like caudally-directed biting 
and scratching behavior when administered to mice [22]. The SP metabolite 1-7 is generated by 
endopeptidase 24.11 [23-25] and also by angiotensin converting enzyme (ACE) [26, 27]. This metabolite 
has been shown to enhance dopamine release, to increase the concentration of dihydroxyphenylacetic 
acid in the brain [28] and to down-regulate NO synthesis [29]. 
Two of the metabolites that were observed in these studies (SP 1-4 and SP 5-11) are formed 
simultaneously by two different enzymes, endopeptidase EC 3.4.21.26 [18, 19] and SP-degrading 
endopeptidase [30].  Both enzymes cleave SP at the Gln5-Gln6 bond.  Metabolite 1-4 has been shown to 
significantly increase dopamine outflow [31] while SP 5-11 increases the release of Asp, Glu, Asn, Gly, 
and taurine [32]. Matrix metalloproteinase-9 has been shown to cleave SP to produce SP 1-9 [33].  As 
with metabolite SP 1-4, SP 1-9 has been determined to significantly increase dopamine outflow [34].  
The Substance P metabolite 6-11 is formed by both SP-degrading endopeptidase [30] and matrix 
metalloproteinase-9 [33]. This metabolite was demonstrated to stimulate an 8-fold increase in NK-1R 
phosphorylation [35] and has also been shown to decrease striatal dopamine release [36].  While the 
metabolite SP 2-11 has been shown to be producedby the hydrolysis of the Arg1-Pro2 bond with 
aminopeptidase P [37] there have been no reports to date of its biological activity.  
Thes results presented here, when taken in conjunction with similar results obtained from in-
vivo studies, indicate that BBB and other endothelial tissues constitute the major sites for the 
metabolism of SP released in the periphery and thus play an important role in the pharmacological and 
toxic effects of SP metabolites.  
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 Conclusion: 
 The results of SP metabolism at the BBB from this study correlate well with in vivo results 
obtained using LC-MS/MS analysis as well as with previous work using BBMECs. Two previously 
unreported metabolites; SP 5-11 and SP 6-11 were found to be produced and were detected at 
physiologically relevant concentrations. This present study also demonstrates that BBMECs can 
potentially be used to investigate the metabolism of neuropeptides at the BBB, without the need for 
complex in vivo experimental procedures.    
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Legends for Figures: 
Table 1:  Precursor ion m/z’s, product ion m/z’s, cone voltages and collision energy values for SP, its 
metabolites and internal standard. 
Table 2: Optimal parameters for SP and metabolites which are held constant for each individual 
compound. 
Table 3: Linearity, linear range and LOD for SP and metabolites in cell media. 
Figure 1: Chromatogram of 1µM SP, metabolites and IS in 50% cell media.  Separation was performed 
using a gradient of 100 % A (0.1 % FA in water) from 0 to 2 minutes, a linear ramp from 2 to 5 minutes 
going from 100 % A to 75 % A and 25 % B (0.1 % FA in ACN), holding at 75 % A and 25 % B from 5 to 6 
minutes, a linear return from 5 to 10 minutes going from 75 % A and 25 % B to 100 % A 
Figure 2a:  TIC of SP, metabolites and IS showing the stability of 5 µM SP in cell experimental media after 
2 days at 4° C. 
Figure 2b:  TIC showing stability of 5 µM SP in cell experimental media after 24 hours at 37° C (no IS 
added to this sample). 
Figure 2c:  TIC chromatogram of well with cells and blank bank buffer (no SP) after 5 hours. 
Figure 2d: TIC chromatogram of well with a solution of 10 µM SP with no cells  after 5 hours. 
Figure 3: Chromatogram of low intensity metabolites after 10 µM SP has been incubated in wells with 
BBMECs for 5 hours; combined traces of 1-4, 1-7, 1-9, 2-11 and 5-11 are shown. 
Figure 4: Chromatogram of high intensity metabolites after 10 µM SP has been incubated in wells with 
BBMECs for 5 hours; combined traces of IS, 3-11 and 6-11 are shown. 
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Figure 5:  Time profile for metabolism of 10 µM SP in BBMECs (n = 4). 
Figure 6:  Time profile for metabolism of 1 µM SP in BBMECs (n = 4). 
Figure 7:  Time profile for metabolism of 100 nM SP in BBMECs (n = 4). 
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Table 1: 
 
 
Compound Molecular 
weight 
Precursor 
m/z 
Product m/z Cone 
Voltage 
Collision 
Energy 
1-4 497 249.2 70.0 18 30 
1-7 900 450.7 70.1 30 40 
1-9 1104 552.9 120.2 30 40 
1-11 1347 674.6 120.2 35 45 
(Tyr8) 1-11 1364 682.6 104.2 35 40 
2-11 1192 596.4 104.2 25 25 
3-11 1094 547.9 104.2 20 20 
5-11 869 869.4 120.2 40 60 
6-11 741 741.4 120.2 35 55 
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Table 2: 
 
MS/MS tune parameter Parameter setting Parameter unit (N/ A if unit 
less) 
Capillary voltage 2.5 kV 
Extractor 2 V 
RF lens 0 N/A 
Source temperature 100 °C 
Desolvation temperature 350 °C 
Desolvation gas flow 675 L/hr 
Cone gas flow 40 L/hr 
LM and HM 1 resolution 12 N/A 
Ion energy 1 0.5 N/A 
Entrance 2 N/A 
Exit 1 N/A 
LM and HM 2 resolution 15 N/A 
Ion energy 2 2 N/A 
Multiplier voltage 650 V 
Gas cell pirani pressure 3.6 e-3 (argon) mbar 
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Table 3: 
 
 
 
 
Compound Linear Range 
(nM) in 50% cell 
media 
Linearity (R2) in 
50% cell media  
LOD (nM) in 
50% cell media  
1-4 50-1000 0.990 50 
1-7 2-500 0.974 2 
1-9 1-1000 0.990 1 
1-11 1-500 0.983 1 
2-11 1-500 0.985 < 1 
3-11 1-500 0.990 < 1 
5-11 1-500 0.979 1 
6-11 1-500 0.989 1 
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Figure 1 
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Figure 2a: 
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Figure 2b 
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Figure 2c 
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Figure 2d 
Time (min)
0 2 4 6 8 10
Io
n 
In
te
ns
ity
0
1e+6
2e+6
3e+6
4e+6
5e+6
1-11
IS
3-11
 
 
 
  
 
 
 
 
 
 
 
Chappa, A.K., Cooper, J.D., Audus, K.L., and Lunte, S.M. (2007) Investigation of the metabolism of Substance-P at the blood-
brain barrier using LC-MS/MS.  J. Pharm. Biomed. Anal.43, 1409-1415.  PMID: 17118606.  Publisher’s official version: 
<http://dx.doi.org/10.1016/j.jpba.2006.10.005> .  Open Access version:  http://kuscholarworks.ku.edu/dspace/. 
23 
 
Figure 3 
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Figure 4 
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Figure 5 
Time (min) after 10µM SP introduction
0 50 100 150 200 250 300 350
C
on
ce
nt
ra
tio
n 
(n
M
)
0
200
400
600
800
1000
1200
1400
1600
6-11 
5-11 
2-11 
3-11 
1-7 
1-4 
1-9 
 
 
 
 
 
 
 
 
 
 
 
 
Chappa, A.K., Cooper, J.D., Audus, K.L., and Lunte, S.M. (2007) Investigation of the metabolism of Substance-P at the blood-
brain barrier using LC-MS/MS.  J. Pharm. Biomed. Anal.43, 1409-1415.  PMID: 17118606.  Publisher’s official version: 
<http://dx.doi.org/10.1016/j.jpba.2006.10.005> .  Open Access version:  http://kuscholarworks.ku.edu/dspace/. 
26 
 
Figure 6 
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Figure 7 
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